Strategic services FinnBrit Consulting operates at the intersection of pharmaceutical development and intellectual property, offering preformulation through process design and manufacturing support along with patent review and expert witness services. Leverage cross-selling opportunities by presenting integrated CMC and IP assessment packages to pharma and biotech clients pursuing new drug programs or licensure.

Mergers and acquisitions The firm provides diligence reviews for in-licensing, mergers, and acquisitions, including viability of CMC programs and formulation IP reviews. Target mid-market pharma companies and biotech firms engaged in M&A activity with needs for due diligence, enabling a bundled offering for deal-ready risk assessment.

Small team agility With a lean team of 2-10 employees, FinnBrit can position itself as a boutique, high-touch consulting partner for early-stage to mid-stage drug programs, emphasizing rapid turnaround, specialized expertise, and flexible engagement models to win project-based or retainer work.

Regional focus Based in Waltham, MA, the company can leverage proximity to Boston-area biopharma clusters for targeted outreach to biotech startups, contract development and manufacturing organizations (CDMOs), and academic spinouts seeking CMC and IP guidance for early development and commercialization.

Revenue leverage With reported revenue in the mid-dollar-millions range, there is room to expand services into larger-scale IP strategy, regulatory-compliant documentation, and full program management for larger customers, while maintaining the flexibility of advisory and expert witness offerings to upsell to ongoing engagement.